BR9713254A - Vacina viva contra helicobacter pylori - Google Patents

Vacina viva contra helicobacter pylori

Info

Publication number
BR9713254A
BR9713254A BR9713254-3A BR9713254A BR9713254A BR 9713254 A BR9713254 A BR 9713254A BR 9713254 A BR9713254 A BR 9713254A BR 9713254 A BR9713254 A BR 9713254A
Authority
BR
Brazil
Prior art keywords
helicobacter pylori
live vaccine
pylori live
vaccines
pylori
Prior art date
Application number
BR9713254-3A
Other languages
English (en)
Inventor
Thomas F Meyer
Rainer Haas
Yan Zhenxin
Oscar Gomez-Duarte
Bernadette Lucas
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BR9713254A publication Critical patent/BR9713254A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção:<B>"VACINA VIVA CONTRA HELICOBACTER PYLORI"<D>. A presente invenção se refere a novas vacinas vivas recombinantes, que conferem imunidade protetora contra uma infecção por Helicobacter pylori, e a um método de triagem de H. pylori para vacinas otimizadas.
BR9713254-3A 1996-10-11 1997-09-01 Vacina viva contra helicobacter pylori BR9713254A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96116337A EP0835928A1 (en) 1996-10-11 1996-10-11 Helicobacter pylori live vaccine
PCT/EP1997/004744 WO1998016552A1 (en) 1996-10-11 1997-09-01 Helicobacter pylori live vaccine

Publications (1)

Publication Number Publication Date
BR9713254A true BR9713254A (pt) 1999-11-03

Family

ID=8223286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713254-3A BR9713254A (pt) 1996-10-11 1997-09-01 Vacina viva contra helicobacter pylori

Country Status (15)

Country Link
EP (2) EP0835928A1 (pt)
JP (1) JP2001510986A (pt)
KR (1) KR100510928B1 (pt)
CN (1) CN1215167C (pt)
AT (1) ATE392429T1 (pt)
AU (1) AU734635B2 (pt)
BR (1) BR9713254A (pt)
CA (1) CA2268033A1 (pt)
DE (1) DE69738641D1 (pt)
IL (1) IL129366A0 (pt)
NO (1) NO991692L (pt)
NZ (1) NZ335050A (pt)
PL (1) PL332575A1 (pt)
TR (1) TR199901450T2 (pt)
WO (1) WO1998016552A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
NZ509127A (en) * 1998-06-19 2004-01-30 Merieux Oravax Use of LT (E. coli) and CT (cholera toxin) for inducing immune responses against helicobacter infection
AU8464398A (en) * 1998-07-16 2000-02-07 Cheil Jedang Corporation Urease based vaccine against (helicobacter) infection
WO2001083531A1 (en) * 2000-04-27 2001-11-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying helicobacter antigens
CN103261214B (zh) * 2010-12-22 2016-10-26 英特维特国际股份有限公司 具有活细菌分离物的用于全身施用的疫苗
US10913781B2 (en) 2011-04-08 2021-02-09 Tufts Medical Center, Inc. Pepducin design and use
AU2016354478B2 (en) 2015-11-13 2021-07-22 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
CN112048008B (zh) * 2020-08-12 2021-06-15 河北医科大学第四医院（河北省肿瘤医院） 一种幽门螺杆菌b细胞耐受表位及其制备的抗体
CN112143741B (zh) * 2020-09-07 2022-09-20 中国科学院南海海洋研究所 一种生物膜基因岛GIVal43097及其切除方法
CN112190704B (zh) * 2020-10-13 2022-11-15 宁夏医科大学 M细胞靶向性重组乳酸菌疫苗及制备方法与应用
CN112143750B (zh) * 2020-10-13 2022-12-27 宁夏医科大学 靶向m细胞的重组乳酸菌表面展示系统、重组乳酸菌疫苗及制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
DE4041045A1 (de) * 1990-12-20 1992-07-02 Max Planck Gesellschaft Zweiphasen-systeme fuer die produktion und praesentation von fremdantigen in hybriden lebendimpfstoffen
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
JPH08509873A (ja) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
EP0654273A1 (en) * 1993-11-18 1995-05-24 Harry H. Leveen Pharmaceutical product and method for treatment
AU5523196A (en) * 1995-02-27 1996-09-18 Enteron Limited Partnership Methods and compositions for production of customized vaccines for diseases associated with antigens of microorganisms
WO1996033732A1 (en) * 1995-04-28 1996-10-31 Oravax, Inc. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
AU734635B2 (en) 2001-06-21
NO991692L (no) 1999-06-04
CA2268033A1 (en) 1998-04-23
EP0835928A1 (en) 1998-04-15
WO1998016552A1 (en) 1998-04-23
CN1215167C (zh) 2005-08-17
EP0931093A1 (en) 1999-07-28
ATE392429T1 (de) 2008-05-15
EP0931093B1 (en) 2008-04-16
KR20000049090A (ko) 2000-07-25
AU4208497A (en) 1998-05-11
CN1246867A (zh) 2000-03-08
NO991692D0 (no) 1999-04-09
DE69738641D1 (de) 2008-05-29
KR100510928B1 (ko) 2005-08-31
JP2001510986A (ja) 2001-08-07
PL332575A1 (en) 1999-09-27
TR199901450T2 (xx) 1999-10-21
NZ335050A (en) 2000-08-25
IL129366A0 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
BR9713254A (pt) Vacina viva contra helicobacter pylori
PT1401489E (pt) Solubilizacao de polissacaridos capsulares
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
DE69426051D1 (de) Infektiösen Bronchitis Virus 4/91 enthaltender Geflügel-Impfstoff
ZA934736B (en) Deletion mutants as vaccines for cholera
DK0745387T3 (da) Adjuvanser til virale vacciner
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
ATE274355T1 (de) Impfstoffe-zusammensetzungen die inaktivierte immunogene und lebende hühner-anäemie-virus enthalten
WO1998040097A3 (en) Bovine respiratory and enteric coronavirus as a vaccine
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
BR0007855A (pt) Vacina de vìrus eliminado o gene bhv-1
SE9702242D0 (sv) Vaccine compositions V
PL346195A1 (en) Chicken anaemia virus (cav) of weakened patogenicity, vaccine for protecting poultry against cav and method of obtaining cav of weakened pathogenicity
PL337472A1 (en) Method of obtaining glycoproteinous compositions, glycoproteinous compositions as such and method of distinguishing actually infected animals from those being vaccinated with a deletion vaccine
SE9702240D0 (sv) Vaccine compositions III

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI ( LEI 9279/96 ) 2O , O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAOPATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.